2013
Systolic Blood Pressure and Cardiovascular Outcomes During Treatment of Hypertension
Weber MA, Bakris GL, Hester A, Weir MR, Hua TA, Zappe D, Dahlof B, Velazquez EJ, Pitt B, Jamerson K. Systolic Blood Pressure and Cardiovascular Outcomes During Treatment of Hypertension. The American Journal Of Medicine 2013, 126: 501-508. PMID: 23541376, DOI: 10.1016/j.amjmed.2013.01.007.Peer-Reviewed Original ResearchConceptsSystolic blood pressureHigh-risk hypertensive patientsPrimary end pointBlood pressure levelsSystolic bloodBlood pressureCardiovascular deathCardiovascular eventsCardiovascular outcomesCoronary eventsEnd pointHypertensive patientsMyocardial infarctionSystolic blood pressure levelsAvoiding Cardiovascular EventsSystolic Hypertension (ACCOMPLISH) trialTotal myocardial infarctionBlood pressure groupMajor cardiovascular eventsMean patient ageNonfatal myocardial infarctionCardiovascular event ratesRenal end pointsLower blood pressureTreatment of hypertension
2012
Effects of body size and hypertension treatments on cardiovascular event rates: subanalysis of the ACCOMPLISH randomised controlled trial
Weber MA, Jamerson K, Bakris GL, Weir MR, Zappe D, Zhang Y, Dahlof B, Velazquez EJ, Pitt B. Effects of body size and hypertension treatments on cardiovascular event rates: subanalysis of the ACCOMPLISH randomised controlled trial. The Lancet 2012, 381: 537-545. PMID: 23219284, DOI: 10.1016/s0140-6736(12)61343-9.Peer-Reviewed Original ResearchConceptsCardiovascular event ratesBody mass indexNormal weightPrimary endpointObese patientsEvent ratesCardiovascular outcomesCardiovascular protectionHypertension treatmentObese individualsHigher cardiovascular event ratesHigh-risk hypertensive patientsNon-fatal myocardial infarctionAmlodipine-based therapyAvoiding Cardiovascular EventsPatient’s cardiovascular outcomeSuperior cardiovascular protectionSystolic Hypertension (ACCOMPLISH) trialPrimary event rateSingle-pill combinationPrevious clinical trialsNormal weight categoryCardiovascular deathCardiovascular eventsHypertension trials
2008
High-risk myocardial infarction in the young: The VALsartan In Acute myocardial iNfarcTion (VALIANT) trial
Anderson RE, Pfeffer MA, Thune JJ, McMurray JJ, Califf RM, Velazquez E, White HD, Rouleau JL, Skali H, Maggioni A, Solomon SD. High-risk myocardial infarction in the young: The VALsartan In Acute myocardial iNfarcTion (VALIANT) trial. American Heart Journal 2008, 155: 706-711. PMID: 18371480, DOI: 10.1016/j.ahj.2007.11.016.Peer-Reviewed Original ResearchMeSH KeywordsAdultAge FactorsAgedAngiotensin II Type 1 Receptor BlockersAngiotensin-Converting Enzyme InhibitorsCardiovascular DiseasesDiabetes ComplicationsFemaleHumansHypertensionKaplan-Meier EstimateMaleMiddle AgedMortalityMultivariate AnalysisMyocardial InfarctionProportional Hazards ModelsRisk FactorsSex FactorsSmokingSurvivorsTetrazolesValineValsartanConceptsAcute myocardial infarctionAcute Myocardial Infarction trialMyocardial Infarction trialRisk factorsMyocardial infarctionHigh-risk myocardial infarctionCardiovascular event ratesInfluence of hypertensionMultivariate Cox regressionPrognostic risk factorsHistory of MICardiovascular outcomesCurrent smokersLess diabetesYounger patientsCox regressionPost-AMIAdvanced ageRelative riskYoung survivorsAge groupsHypertensionEvent ratesPatientsOutcomes